Clinical Trial

Long-term Use of CCB and Breast Cancer Risk

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this retrospective observational study is to examine whether long-term calcium channel blocker (CCB) use is associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands . The main questions it aims to answer are: * Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association. * Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women. The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-01.
Trial Details
NCT Number NCT05972785
Lead Sponsor Curtin University
Conditions Hypertension,Essential, Breast Cancer
Enrollment 68,500 participants
Start Date 2022-07-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-21